DOMINIQUE GRIFFIN: Open Payments
NPI 1164946992 · CULVER CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 57 payments from 7 companies in 2025. Trend: 2023 $1,415 · 2024 $1,740 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 32 | $329 |
| Alkermes, Inc. | 14 | $207 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $93 |
| Neurocrine BioSciences, Inc. | 5 | $76 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $16 |
Products named: INVEGA SUSTENNA, ARISTADA, CAPLYTA, INGREZZA, FANAPT, ABILIFY ASIMTUFII, ABILIFY MAINTENA.
Industry payments across CA — which companies pay providers there.
